Masand Prakash S, Gupta Sanjay, Schwartz Thomas L, Virk Subhdeep, Hameed Ahmad, Kaplan David S
Department of Psychiatry, Duke University Medical Center, Durham, NC, USA.
Prim Care Companion J Clin Psychiatry. 2005;7(4):162-6. doi: 10.4088/pcc.v07n0404.
This open-label pilot study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram improves symptoms of irritable bowel syndrome (IBS), a functional gastrointestinal disorder with frequent psychiatric comorbidity.
Fifteen patients meeting Rome I criteria for IBS were administered open-label citalopram (20-40 mg/day) for 12 weeks. The study was conducted from October 2000 to August 2001.
Twelve (80%) of the 15 subjects reported a > or = 50% decrease in the presence of abdominal pain, 10 (67%) reported a > or = 50% reduction in the severity of the symptom, and 12 (80%) reported a > or = 50% reduction in the frequency of the symptom. Approximately one half of the patients met criteria for remission (> or = 70% improvement) of abdominal pain.
Results of this pilot study suggest that large controlled trials are needed to further evaluate the efficacy of SSRIs such as citalopram for the treatment of IBS.
这项开放标签的试点研究调查了选择性5-羟色胺再摄取抑制剂（SSRI）西酞普兰是否能改善肠易激综合征（IBS）的症状，IBS是一种常伴有精神疾病共病的功能性胃肠疾病。
15名符合罗马I标准的IBS患者接受了为期12周的开放标签西酞普兰治疗（20 - 40毫克/天）。该研究于2000年10月至2001年8月进行。
15名受试者中有12名（80%）报告腹痛症状减轻了≥50%，10名（67%）报告症状严重程度降低了≥50%，12名（80%）报告症状发作频率降低了≥50%。约一半的患者符合腹痛缓解标准（改善≥70%）。
这项试点研究结果表明，需要进行大规模对照试验来进一步评估西酞普兰等SSRI治疗IBS的疗效。
